JAK2 and neurodegenerative disease: In our study, AG490 (a JAK2-specific inhibitor) was employed, aiming to figure out whether JAK2 involves in inflammation responses in leptomeningeal cells induced by cytokines from macrophages and whether it is a therapeutic target of neurodegenerative diseases.